Maschauer et al., 2014 - Google Patents
In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot studyMaschauer et al., 2014
View HTML- Document ID
- 3809547197299948878
- Author
- Maschauer S
- Ruckdeschel T
- Tripal P
- Haubner R
- Einsiedel J
- Hübner H
- Gmeiner P
- Kuwert T
- Prante O
- Publication year
- Publication venue
- Pharmaceuticals
External Links
Snippet
The neurotensin receptor (NTS1) has emerged as an interesting target for molecular imaging and radiotherapy of NTS-positive tumors due to the overexpression in a range of tumors. The aim of this study was to develop a 177Lu-labeled NTS1 radioligand, its …
- 102000017922 Neurotensin receptor family 0 title abstract description 39
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hennrich et al. | [68Ga] Ga-DOTA-TOC: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging | |
Hennrich et al. | Lutathera®: the first FDA-and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy | |
Varasteh et al. | The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin | |
Mitran et al. | Bispecific GRPR-antagonistic anti-PSMA/GRPR heterodimer for PET and SPECT diagnostic imaging of prostate cancer | |
Kaloudi et al. | NeoBOMB1, a GRPR-antagonist for breast cancer theragnostics: First results of a preclinical study with [67Ga] NeoBOMB1 in T-47D cells and tumor-bearing mice | |
Maschauer et al. | In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study | |
Hu et al. | Radiosynthesis and preclinical evaluation of bispecific PSMA/FAP heterodimers for tumor imaging | |
Abouzayed et al. | Synthesis and preclinical evaluation of radio-iodinated GRPR/PSMA bispecific heterodimers for the theranostics application in prostate cancer | |
Dahlsson Leitao et al. | Molecular design of HER3-targeting affibody molecules: Influence of chelator and presence of HEHEHE-tag on biodistribution of 68Ga-labeled tracers | |
Bendre et al. | Evaluation of Met-Val-Lys as a renal brush border enzyme-cleavable linker to reduce kidney uptake of 68Ga-labeled DOTA-conjugated peptides and peptidomimetics | |
Nock et al. | [99mTc] Tc-DB15 in GRPR-targeted tumor imaging with SPECT: from preclinical evaluation to the first clinical outcomes | |
Wharton et al. | Preclinical Evaluation of [155/161Tb] Tb-Crown-TATE—A Novel SPECT Imaging Theranostic Agent Targeting Neuroendocrine Tumours | |
Maschauer et al. | Theranostic value of multimers: lessons learned from trimerization of neurotensin receptor ligands and other targeting vectors | |
Summer et al. | Pretargeted imaging with Gallium-68—improving the binding capability by increasing the number of tetrazine motifs | |
Klingler et al. | Cholecystokinin-2 receptor targeting with novel c-terminally stabilized HYNIC-Minigastrin analogs radiolabeled with technetium-99m | |
Hörmann et al. | Radiopharmaceutical formulation and preclinical testing of 68Ga-labeled DOTA-MGS5 for the regulatory approval of a first exploratory clinical trial | |
Lundmark et al. | Preclinical characterisation of PSMA/GRPR-targeting heterodimer [68Ga] Ga-BQ7812 for PET diagnostic imaging of prostate cancer: A step towards clinical translation | |
Lo et al. | Molecular imaging and preclinical studies of radiolabeled long-term RGD peptides in U-87 MG tumor-bearing mice | |
Fani et al. | Selection of the first 99mTc-labelled somatostatin receptor subtype 2 antagonist for clinical translation—Preclinical assessment of two optimized candidates | |
Wang et al. | 68Ga-Labeled [Thz14] Bombesin (7–14) analogs: Promising GRPR-targeting agonist PET tracers with low pancreas uptake | |
Trencsényi et al. | Scandium-44: Diagnostic Feasibility in Tumor-Related Angiogenesis | |
Hörmann et al. | Effect of N-terminal peptide modifications on in vitro and in vivo properties of 177Lu-labeled peptide analogs targeting CCK2R | |
Lymperis et al. | Comparing Gly11/dAla11-replacement vs. the in-situ neprilysin-inhibition approach on the tumor-targeting efficacy of the 111In-SB3/111In-SB4 radiotracer pair | |
Baun et al. | Preclinical evaluation of the copper-64 labeled GRPR-antagonist RM26 in comparison with the cobalt-55 labeled counterpart for PET-imaging of prostate cancer | |
Gaonkar et al. | SPECT imaging of SST2-expressing tumors with 99mTc-based somatostatin receptor antagonists: The role of tetraamine, HYNIC, and spacers |